Insider Buying: GSK (LON:GSK) Insider Purchases £123.55 in Stock

GSK plc (LON:GSK) insider Julie Brown bought 7 shares of GSK stock in a transaction dated Friday, October 9th. The stock was purchased at an average price of GBX 1,765 per share, with a total value of £123.55.

Julie Brown also recently made the following trade(s):

• On Wednesday, September 9th, Julie Brown bought 7 shares of GSK stock. The stock was purchased at an average cost of GBX 1,803 per share, for a total transaction of £126.21.

GSK Stock Performance

Shares of LON:GSK traded up GBX 19 during midday trading on Monday, hitting GBX 1,771. The stock had a trading volume of 3,152,165 shares, compared to its average volume of 12,615,232. GSK plc has a 1 year low of GBX 1,592 and a 1 year high of GBX 2,282. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The stock has a 50 day moving average price of GBX 1,858.40 and a two-hundred day moving average price of GBX 1,933.21. The company has a market capitalization of £70.96 billion, a PE ratio of 15.03, a P/E/G ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last posted its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. As a group, equities analysts predict that GSK plc will post 175.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GSK has been the topic of several recent analyst reports. Berenberg Bank boosted their target price on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research report on Tuesday, September 15th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a research note on Wednesday, July 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 1,975 price objective on shares of GSK in a report on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a research report on Tuesday, September 29th. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of GBX 2,064.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.